EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aberrant intra‐epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103 ‐β7‐receptor‐mediated granzyme‐B degranulation which can be restored by etrolizumab

Daan A R Castelijn iD, Jolanda M W van de Water, Laura R de Baaij, Bridget S McGlinchy, Michelle van Leeuwen, Sander P J Joosten, Nikita Alberts, Margherita Rossi, Martine Reijm, Jolien C Hollander, Petra Bonnet, Yvonne M C Kooy-Winkelaar und 7 weitere

Clinical & Translational Immunology · 2026-05 · 15 (5)

DOI: 10.1002/cti2.70099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 14.05.2026. Verfasst von Daan A R Castelijn und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology and Metabolism Research Institute Amsterdam University Medica…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitieren

Abstract (Originalsprache)

Objectives

Refractory celiac disease type II (RCDII) is an intestinal tumor of aberrant intra‐epithelial T‐lymphocytes (IEL). The severe enteropathy found in RCDII is caused by aberrant IEL that exert cytotoxicity against enterocytes. In this study, we investigated the cell death mechanism responsible for villous atrophy in RCDII.

Methods

Aberrant IEL were isolated from duodenal biopsies of RCDII patients. Enterocyte and RCDII patient‐derived cell lines and human small intestinal organoids were used. mRNA expression was determined with reverse transcriptase‐multiplex ligation‐dependent probe amplification. Protein expression, degranulation and enterocyte killing were measured using flow cytometry, immunofluorescence or bright field microscopy. Secretion of granzyme‐B was detected by enzyme immunoassay.

Results

Levels of granzyme‐B expression were significantly upregulated in aberrant IEL of RCDII patients compared to patients with celiac disease (CD) on gluten‐free diet ( P = 0.0001) and correlated with severity of villous atrophy and clinical response to therapy. Killing of intestinal epithelial cells was caused by granzyme‐B. For granzyme‐B degranulation and subsequent cytotoxicity, cell–cell binding via the CD103‐receptor, which was upregulated on aberrant IEL, was essential. In a preclinical model, aberrant IEL migrated to the intestinal organoids and induced organoid disintegration and CD103‐dependent cell death. Targeting CD103‐heterodimeric partner β7 with therapeutic monoclonal antibody etrolizumab prevented enterocyte cell killing and resulted in survival of organoids.

Conclusion

Killing of enterocytes in RCDII patients depends on degranulation of granzyme‐B by aberrant IEL through CD103‐β7 binding. By blocking this interaction, etrolizumab restores the intestinal epithelium and therefore should be considered as potential therapy for RCDII patients.

Schlagwörter

Stichwörter der Autor:innen

autoimmunitycell deathenteropathyintestinal inflammation

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology and Metabolism Research Institute Amsterdam University Medical Centers Amsterdam The Netherlands.
  • Department of Pathology, Amsterdam Gastroenterology Endocrinology and Metabolism Research Institute Amsterdam University Medical Centers Amsterdam The Netherlands.
  • Department of Internal Medicine St. Antonius Hospital Nieuwegein The Netherlands.
  • Department of Clinical Chemistry, Amsterdam Institute for Infection and Immunity Amsterdam University Medical Centers Amsterdam The Netherlands.
  • Department of Immunohematology and Blood Transfusion Leiden University Medical Center Leiden The Netherlands.

ORCID-Profile: Daan A R Castelijn

Zitieren

APA

Castelijn, D. A. R., van de Water, J. M. W., de Baaij, L. R., McGlinchy, B. S., van Leeuwen, M., Joosten, S. P. J., Alberts, N., Rossi, M., Reijm, M., Hollander, J. C., Bonnet, P., Kooy-Winkelaar, Y. M. C., Koning, F., Pals, S. T., Bouma, G., Meijer, C. J. L. M., Bontkes, H. J., Mulder, C. J. J., & Cillessen, S. A. G. M. (2026). Aberrant intra‐epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103 ‐β7‐receptor‐mediated granzyme‐B degranulation which can be restored by etrolizumab. Clinical & Translational Immunology, 15(5). https://doi.org/10.1002/cti2.70099

Vancouver

Castelijn DAR, van de Water JMW, de Baaij LR, McGlinchy BS, van Leeuwen M, Joosten SPJ, et al. Aberrant intra‐epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103 ‐β7‐receptor‐mediated granzyme‐B degranulation which can be restored by etrolizumab. Clinical & Translational Immunology. 2026;15(5). doi:10.1002/cti2.70099

BibTeX
@article{Castelijn2026,
  author = {Castelijn, Daan A R and van de Water, Jolanda M W and de Baaij, Laura R and McGlinchy, Bridget S and van Leeuwen, Michelle and Joosten, Sander P J and Alberts, Nikita and Rossi, Margherita and Reijm, Martine and Hollander, Jolien C and Bonnet, Petra and Kooy-Winkelaar, Yvonne M C and Koning, Frits and Pals, Steven T and Bouma, Gerd and Meijer, Chris J L M and Bontkes, Hetty J and Mulder, Chris J J and Cillessen, Saskia A G M},
  title = {Aberrant intra‐epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103 ‐β7‐receptor‐mediated granzyme‐B degranulation which can be restored by etrolizumab},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cti2.70099}
}
Kostenlos starten →